ALB and neoplasm: Once in the blood stream, 1 binds selectively to the thiol at the cysteine 34 position of circulating albumin through Michael addition.11,12 The presence of albumin on the resulting drug carrier 2 prevents rapid renal elimination while ensuring passive accumulation and retention in malignant tissues due to the anatomical and pathophysiological characteristics of tumour blood vessels.13,14 Hydrolysis of the glycosidic bond by β-glucuronidase which selectively accumulates in the tumour microenvironment15–21 triggers the release of the drug via the self-immolative mechanism depicted in Fig. 1b.